Suppr超能文献

体内化学推进的纳米和微米马达:何去何从?

Chemically Propelled Nano and Micromotors in the Body: Quo Vadis?

机构信息

Departments of Chemistry and Chemical Engineering, The Pennsylvania State University, University Park, PA, 16802, USA.

出版信息

Small. 2021 Feb;17(5):e2007102. doi: 10.1002/smll.202007102. Epub 2021 Jan 12.

Abstract

The active delivery of drugs to disease sites in response to specific biomarkers is a holy grail in theranostics. If successful, it would greatly diminish the therapeutic dosage and reduce collateral cytotoxicity. In this context, the development of nano and micromotors that are able to harvest local energy to move directionally is an important breakthrough. However, serious hurdles remain before such active systems can be employed in vivo in therapeutic applications. Such motors and their energy sources must be safe and biocompatible, they should be able to move through complex body fluids, and have the ability to reach specific cellular targets. Given the complexity in the design and deployment of nano and micromotors, it is also critically important to show that they are significantly superior to inactive "smart" nanoparticles in theranostics. Furthermore, receiving regulatory approval requires the ability to scale-up the production of nano and micromotors with uniformity in structure, function, and activity. In this essay, the limitations of the current nano and micromotors and the issues that need to be resolved before such motors are likely to find theranostic applications are discussed.

摘要

主动将药物递送到疾病部位以响应特定的生物标志物是治疗学中的圣杯。如果成功,它将大大减少治疗剂量并降低细胞毒性。在这种情况下,开发能够利用局部能量来定向移动的纳米和微马达是一个重要的突破。然而,在这些主动系统能够在治疗应用中在体内使用之前,仍然存在严重的障碍。这些马达及其能源必须安全且具有生物相容性,它们应该能够在复杂的体液中移动,并具有到达特定细胞靶标的能力。鉴于纳米和微马达的设计和部署的复杂性,展示它们在治疗学中明显优于非活性“智能”纳米颗粒也非常重要。此外,获得监管批准需要能够以结构、功能和活性的均一性来扩大纳米和微马达的生产。在本文中,讨论了当前纳米和微马达的局限性以及这些马达在可能找到治疗应用之前需要解决的问题。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验